Cefixime

Dosing

Usual doseUncomplicated gonorrheaPharyngitis, tonsillitis400 mg PO #1-2400 mg PO 1 dose400 mg PO #1-2 x10d

Safety and efficacy in pediatric patients <6m of age have not been establishedCefixime tablet or capsule is not bioequivalent with chewable tablet or suspension- BW 5-7.5 kg 50 mg/kg PO #1-2

  • BW 7.6-10 kg 80 mg/kg PO #1-2

  • BW 10.1-12.5 kg 100 mg/kg PO #1-2

  • BW 12.5-20.5 kg 150 mg/kg PO #1-2

  • BW 20.6-28 kg 200 mg/kg PO #1-2

  • BW 28.1-33 kg 250 mg/kg PO #1-2

  • BW 33.1-40 kg 300 mg/kg PO #1-2

  • BW 40.1-45 kg 350 mg/kg PO #1-2

  • BW >45 kg or age >12y Refer to adult dose

No dose adjustment

CrCl >60CrCl 21-60, HDCrCl <20, CAPDCRRTNo dose adjustment75% recommended dose PO q24h50% recommended dose PO q24hNo data

General Information

  • Gonorrhea

  • Otitis media

  • Pharyngitis

  • Tonsillitis

  • Urinary tract infectious disease, uncomplicated

  • Acute infective exacerbation of chronic obstructive pulmonary disease

Test of cure with culture or nucleic acid amplification test 14 days after treatment for pharyngeal gonorrhea.

Monitor prothrombin time in high risk patients (i.e. those with renal or hepatic impairment, poor nutritional status, prolonged treatment duration, and/or those previously stabilized on concomitant anticoagulation therapy).

Monitor dialysis patients closely.

Common

  • Abdominal pain

  • Diarrhea

  • Nausea

  • Flatulence

  • Indigestion

Serious

  • Erythema multiforme

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis

  • Anaphylaxis

  • Acute renal failure

  • Angioedema

  • Warfarin - increased risk of bleeding

  • Cholera vaccine, live

  • Combination oral contraceptives

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 3-4 hours

Urine penetration: Therapeutic

Precautions:

  • Exercise caution and adjust dose in patients with renal impairment and those on continuous ambulatory peritoneal dialysis and hemodialysis; monitoring recommended.

  • Discontinuation of antibacterial use not directed against C. difficile may be required.

  • Cross-sensitivity may occur in patients with penicillin-sensitivity.

  • Use caution and consider the total daily amount of phenylalanine intake in patients with phenylketonuria.

  • Use of nitroferricyanide and glucose tests using enzymatic glucose oxidase reactions are recommended.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.